This can be achieved by using CRISPR/Cas9 or transcription-activator-like effector nucleases (TALENs) to knock out the TCRα chain (TRAC) or β2 microglobulin of the MHC molecule, to prevent alloreactive T cells from inducing GvHD [233,234]. Here, HLA-G is linked to graft versus host disease.